Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zr-Df-IAB22M2C Infusion · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| ⁸⁹Zr-Df-IAB22M2C Infusion | EXPERIMENTAL | 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes |
| Name | Type | Description |
|---|---|---|
| ⁸⁹Zr-Df-IAB22M2C Infusion | DRUG | A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes. |
Inclusion Criteria: 1. Patients with selected solid malignancies (NSCLC, SCLC, SqCCHN, melanoma, merkel cell tumor, renal, bladder, hepatocellular, triple negative breast, or gastroesophageal cancer) or Hodgkin's lymphoma 2. At least 1 measurable lesion documented on CT/MRI (RECIST criteria 1.1) 3....
⁸⁹Zr-Df-IAB22M2C Infusion is an investigational small molecule being developed for use in positron-emission tomography (PET) imaging. It is intended for patients with selected solid malignancies or Hodgkin's lymphoma, as part of an oncology imaging approach. The drug is currently in clinical development and is not yet approved.
⁸⁹Zr-Df-IAB22M2C Infusion is being developed by Telix Pharmaceuticals Limited, a biopharmaceutical company. Telix is publicly traded under the ticker symbol TLX. The company is conducting clinical research to evaluate this investigational imaging agent for oncology applications.
⁸⁹Zr-Df-IAB22M2C Infusion is in Phase 1 clinical development. It is an investigational agent, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under investigation for its intended use in PET imaging.
⁸⁹Zr-Df-IAB22M2C Infusion has been studied in one completed Phase 1 clinical trial, identified as NCT03107663. This trial evaluated the drug in patients with selected solid malignancies or Hodgkin's lymphoma. The study enrolled 15 participants and was conducted in the United States.
⁸⁹Zr-Df-IAB22M2C Infusion is a small molecule designed for use in positron-emission tomography (PET) imaging. It is being investigated for imaging in oncology, specifically for conditions such as metastatic solid malignancies and Hodgkin lymphoma. The drug's mechanism involves immunomodulation, as indicated in the clinical trial context.